Acne Vulgaris - Pipeline Review, H1 2018

  • ID: 4529317
  • Report
  • 182 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Cutanea Life Sciences Inc
  • Galderma SA
  • Melinta Therapeutics Inc
  • Novartis AG
  • Phosphagenics Ltd
  • MORE
Acne Vulgaris - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2018, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights:

This latest pipeline guide Acne Vulgaris - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 20, 5, 1, 16 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Cutanea Life Sciences Inc
  • Galderma SA
  • Melinta Therapeutics Inc
  • Novartis AG
  • Phosphagenics Ltd
  • MORE
Introduction

Acne Vulgaris - Overview

Acne Vulgaris - Therapeutics Development

Acne Vulgaris - Therapeutics Assessment

Acne Vulgaris - Companies Involved in Therapeutics Development

Acne Vulgaris - Drug Profiles

Acne Vulgaris - Dormant Projects

Acne Vulgaris - Discontinued Products

Acne Vulgaris - Product Development Milestones

Appendix

List of Tables

Table 1: Number of Products under Development for Acne Vulgaris, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Universities/Institutes, H1 2018

Table 6: Products under Development by Companies, H1 2018

Table 7: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 8: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 9: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 10: Products under Development by Universities/Institutes, H1 2018

Table 11: Number of Products by Stage and Target, H1 2018

Table 12: Number of Products by Stage and Mechanism of Action, H1 2018

Table 13: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 14: Number of Products by Stage and Route of Administration, H1 2018

Table 15: Number of Products by Stage and Molecule Type, H1 2018

Table 16: Acne Vulgaris - Pipeline by 3SBio Inc, H1 2018

Table 17: Acne Vulgaris - Pipeline by BioPharmX Inc, H1 2018

Table 18: Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H1 2018

Table 19: Acne Vulgaris - Pipeline by Cassiopea SpA, H1 2018

Table 20: Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H1 2018

Table 21: Acne Vulgaris - Pipeline by Daewoong Co Ltd, H1 2018

Table 22: Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2018

Table 23: Acne Vulgaris - Pipeline by ELORAC Inc, H1 2018

Table 24: Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H1 2018

Table 25: Acne Vulgaris - Pipeline by Galderma SA, H1 2018

Table 26: Acne Vulgaris - Pipeline by Helix BioMedix Inc, H1 2018

Table 27: Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Table 28: Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018

Table 29: Acne Vulgaris - Pipeline by LEO Pharma A/S, H1 2018

Table 30: Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, H1 2018

Table 31: Acne Vulgaris - Pipeline by Novabiotics Ltd, H1 2018

Table 32: Acne Vulgaris - Pipeline by Novan Inc, H1 2018

Table 33: Acne Vulgaris - Pipeline by Novartis AG, H1 2018

Table 34: Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H1 2018

Table 35: Acne Vulgaris - Pipeline by Pfizer Inc, H1 2018

Table 36: Acne Vulgaris - Pipeline by Phagelux Inc, H1 2018

Table 37: Acne Vulgaris - Pipeline by Phosphagenics Ltd, H1 2018

Table 38: Acne Vulgaris - Pipeline by Photocure ASA, H1 2018

Table 39: Acne Vulgaris - Pipeline by Promius Pharma LLC, H1 2018

Table 40: Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H1 2018

Table 41: Acne Vulgaris - Pipeline by Realm Therapeutics Plc, H1 2018

Table 42: Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018

Table 43: Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H1 2018

Table 44: Acne Vulgaris - Pipeline by Sun Pharmaceutical Industries Ltd, H1 2018

Table 45: Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H1 2018

Table 46: Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H1 2018

Table 47: Acne Vulgaris - Pipeline by XBiotech Inc, H1 2018

Table 48: Acne Vulgaris - Dormant Projects, H1 2018

Table 49: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 50: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..2), H1 2018

Table 51: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..3), H1 2018

Table 52: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..4), H1 2018

Table 53: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..5), H1 2018

Table 54: Acne Vulgaris - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Acne Vulgaris, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Top 10 Targets, H1 2018

Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Routes of Administration, H1 2018

Figure 9: Number of Products by Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • BioPharmX Inc
  • Braintree Laboratories Inc
  • Cassiopea SpA
  • Cutanea Life Sciences Inc
  • Daewoong Co Ltd
  • Deltanoid Pharmaceuticals Inc
  • ELORAC Inc
  • Foamix Pharmaceuticals Ltd
  • Galderma SA
  • Helix BioMedix Inc
  • Innovation Pharmaceuticals Inc
  • Lee's Pharmaceutical Holdings Ltd
  • LEO Pharma A/S
  • Melinta Therapeutics Inc
  • Novabiotics Ltd
  • Novan Inc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Phagelux Inc
  • Phosphagenics Ltd
  • Photocure ASA
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Realm Therapeutics Plc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Sun Pharmaceutical Industries Ltd
  • Valeant Pharmaceuticals International Inc
  • Vyome Biosciences Pvt Ltd
  • XBiotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll